<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-16008283</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-04-14</date_registration>
      <primary_sponsor>Department of hematology,Xinqiao Hospital,Third Military Medical University,Chongqing,China</primary_sponsor>
      <public_title>Clinical trial of foscarnet and ganciclovir for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Clinical trial of foscarnet and ganciclovir for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-04-01</date_enrolment>
      <type_enrolment />
      <target_size>test group:126;control group:126;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=14024</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>cytomegalovirus infection</hc_freetext>
      <i_freetext>test group:Receive foscarnet for prevention of cytomegalovirus infection from engraftment to day+60 after transplantation;control group:Receive ganciclovir for prevention of cytomegalovirus infection from engraftment to day+60 after transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Xuan Zhang</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15736263620</telephone>
        <email>572739688@qq.com</email>
        <affiliation>Department of hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xi Zhang</firstname>
        <middlename />
        <lastname />
        <address>重庆市沙坪坝区新桥正街183号</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13808310064</telephone>
        <email>zhangxxi@sina.com</email>
        <affiliation>Department of hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Aged 12 to 55 years;
2. Patients undergoing allogeneic hematopoietic stem cell transplantation for  hematology diseases;
3. Seronegative for CMV IgM; negative for CMV DNA in blood and urine;
4. Understand and voluntarily sign an informed consent.</inclusion_criteria>
      <agemin>12</agemin>
      <agemax>55</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Absolute neutrophil count &lt;0.5*10^9/L,platelet count &lt;25*10^9/L;
2. serum creatinine &gt; 105umol/L; ALT, AST and total bilirubin&gt; 2 times upper limit of normal value;
3. Ongoing antiviral treatment with acyclovir,ganciclovir or foscarnet;
4. Allergy to foscarnet or ganciclovir;
5. Pregnant or lactating women.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incidence of CMV infection within 100 days after transplantation;Survival rate within 100 days after transplantation;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Incidence of CMV disease within 100 days after transplantation;Incidence of durg-related adverse events;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-paying</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-03-30</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>